Are there any published clinical trials of UroVaxom (OM‑89) or StroVac (Solco‑Urovac) conducted in Balkan countries?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Istraživanja UroVaxom-a i StroVac-a na Balkanu

Ne postoje objavljeni podaci o kliničkim ispitivanjima UroVaxom-a (OM-89) ili StroVac-a (Solco-Urovac) specifično sprovedenim u balkanskim zemljama.

Geografska distribucija dostupnih istraživanja

Pregled dostupne literature pokazuje da su klinička ispitivanja ovih vakcina uglavnom sprovedena u sledećim regionima:

UroVaxom (OM-89)

  • Nemačka - najveće multicentrično ispitivanje sa 453 pacijentkinje 1
  • Švajcarska - jedno ispitivanje sa 188 pacijenata 1
  • Italija - nekoliko studija 1
  • Austrija - manje studije 1
  • Meksiko - nedavno retrospektivno ispitivanje sa 208 žena 2

StroVac (Solco-Urovac)

  • Norveška - jedno ispitivanje 1
  • Sjedinjene Američke Države - nekoliko studija 1

Zašto je ovo važno

Iako nema specifičnih balkanskih studija, meta-analize pokazuju da OM-89 (UroVaxom) značajno smanjuje stopu rekurentnih urinarnih infekcija (RR 0.61,95% CI 0.48-0.78) 1, 3. Međutim, najnovija meta-regresija iz 2025. godine otkriva zabrinjavajući trend: efikasnost OM-89 opada u novijim istraživanjima 4.

Za StroVac, dokazi su heterogeni - dok observacione studije pokazuju povoljne rezultate, jedino randomizovano kontrolisano ispitivanje nije pokazalo superiornost u odnosu na placebo (p=0.63) 5.

Klinička implikacija

Odsustvo balkanskih studija ne znači da ovi preparati nisu efikasni u toj populaciji, ali:

  • Lokalni obrasci antimikrobne rezistencije mogu se razlikovati
  • Genetske i mikrobiomske razlike u populaciji mogu uticati na odgovor
  • Specifični sojevi E. coli koji cirkulišu na Balkanu mogu biti različiti od onih u studijama

Preporuka je da se OM-89 može razmotriti kao opcija za prevenciju rekurentnih urinarnih infekcija 1, ali sa svešću da najnoviji dokazi pokazuju smanjenu efikasnost 4.

References

Related Questions

Which bacterial vaccine, UroVaxom (OM‑89) or Solco‑Urovac/Strovac, is more effective for preventing recurrent urinary tract infections according to research?
How should Urovax (OM‑89) be administered?
In which countries have the clinical trials for UroVaxom (OM‑89) and StroVac (Solco‑Urovac) been conducted?
Can a clinical trial be conducted in Bosnia to assess the efficacy of OM‑89 (UroVaxom) or StroVac for preventing recurrent urinary tract infections, and what sample size is needed?
Can you provide studies on UroVaxom (OM‑89) and StroVac (Solco‑Urovac)?
Why would a clinician choose pitavastatin for treating hyperlipidemia?
Can you provide studies on UroVaxom (OM‑89) and StroVac (Solco‑Urovac)?
In which countries have the clinical trials for UroVaxom (OM‑89) and StroVac (Solco‑Urovac) been conducted?
What is the maximum daily dose of intravenous paracetamol (acetaminophen) for an adult?
Does adalimumab (Humira) reduce healthcare utilization in inflammatory bowel disease, including hospitalizations and surgeries?
What are the possible causes of red blood cells and white blood cells in urine when a urinary tract infection is absent?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.